核酸检测在前列腺癌诊断中的研究现状

丁辉; 吴振启

doi:10.13201/j.issn.1001-1420.2016.09.022

核酸检测在前列腺癌诊断中的研究现状

丁辉,
吴振启^,

- 复旦大学附属中山医院青浦分院泌尿外科(上海, 200000)

详细信息

通讯作者: 吴振启,E-mail:wzq0719@hotmail.com

中图分类号: R737.25

收稿日期: 2016-08-09

Current situation of research of nucleic acid detection in diagnosis of prostate cancer

DING Hui,
WU Zhenqi^,

- Department of Urology, Zhongshan Hospital Affiliated to Fudan University of Qingpu Branch, Shanghai, 200000, China

More Information

Corresponding author: WU Zhenqi, E-mail: wzq0719@hotmail.com

Received Date: 09 August 2016

摘要

摘要: 前列腺特异性抗原(PSA)作为诊断前列腺癌最常用的标志物,提高了早期前列腺癌的发现率,但其特异性不高,造成PSA灰区的患者过度诊断和治疗。随着大量分子检测技术的涌现,核酸检测已成为能够显著提高前列腺癌诊断率的方法之一。DNA中的融合基因TMPRSS2-ERG、PTEN丢失、线粒体DNA过量表达以及其3.4kb丢失在前列腺癌发生和发展中起到重要作用,一种被称为ConfirmMDX用于检测表观遗传现象的技术显著提高了前列腺癌诊断特异性。RNA中的前列腺特异性抗原3、微小RNA、肺腺癌转录相关转移物1在诊断前列腺癌中的价值也备受关注。本文对此进行了综述。
- 前列腺癌 /
- 核酸检测 /
- 脱氧核糖核酸 /
- 核糖核酸
Abstract: Prostate specific antigen(PSA)is the most commonly used marker for the diagnosis of prostate cancer,which improves the detection rate of early prostate cancer.But its specificity is not high,resulting in excessive diagnosis and treatment of patients with PSA gray area.With the emergence of a large number of molecular detection techniques,nucleic acid detection has become one of the ways to significantly improve the diagnostic rate of prostate cancer.Fusion gene TMPRSS2-ERG,Loss of PTEN gene,excessive expression of mitochondrial DNA and loss of 3.4kb play an important role in the occurrence and development of prostate cancer.ConfirmMDX known as a technology for the detection of epigenetic phenomena can significantly improve the diagnostic specificity of prostate cancer.The value of prostate specific antigen 3,micro RNA,lung adenocarcinoma transcription related metastasis 1in the diagnosis of prostate is also highly concerned.
- prostate cancer /
- nucleic acid detection /
- deoxyribonucleic acid /
- ribonucleic acid

HTML全文

参考文献(42)

[1]	Siegel R,Naishadham D,Jemal A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.
[2]	Dijkstra S,Mulders P F,Schalken J A.Clinical use of novel urine and blood based prostate cancer biomarkers:a review[J].Clin Biochem,2014,47(10-11):889-896.
[3]	Xia J,Gulati R,Au M,et al.Effects of screening on radical prostatectomy efficacy:the prostate cancer intervention versus observation trial[J].J Natl Cancer Inst,2013,105(8):546-550.
[4]	Lin R,Maeda S,Liu C,et al.A large noncoding RNAis a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas[J].Oncogene,2007,26(6):851-858.
[5]	Bussemakers M J,van Bokhoven A,Verhaegh G W,et al.DD3:a new prostate-specific gene,highly overexpressed in prostate cancer[J].Cancer Res,1999,59(23):5975-5979.
[6]	de Kok J B,Verhaegh G W,Roelofs R W,et al.DD3(PCA3),a very sensitive and specific marker to detect prostate tumors[J].Cancer Res,2002,62(9):2695-2698.
[7]	Thuret R,Chantrel-Groussard K,Azzouzi A R,et al.Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer[J].Br J Cancer,2005,92(2):236-240.
[8]	Auprich M,Chun F K,Ward J F,et al.Critical assessment of preoperative urinary prostate cancer antigen 3on the accuracy of prostate cancer staging[J].Eur Urol,2011,59(1):96-105.
[9]	Sartori D A,Chan D W.Biomarkers in prostate cancer:what's new[J]?Curr Opin Oncol,2014,26(3):259-264.
[10]	Crawford E D,Rove K O,Trabulsi E J,et al.Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen:aprospective study of 1,962cases[J].J Urol,2012,188(5):1726-1731.
[11]	Cary K C,Cooperberg M R.Biomarkers in prostate cancer surveillance and screening:past,present,and future[J].Ther Adv Urol,2013,5(6):318-329.
[12]	Vlaeminck-Guillem V,Ruffion A,AndréJ,et al.Urinary prostate cancer 3test:toward the age of reason[J]?Urology,2010,75(2):447-453.
[13]	Tombal B,Andriole G L,de la Taille A,et al.Clinical judgment versus biomarker prostate cancer gene 3:which is best when determining the need for repeat prostate biopsy[J]?Urology,2013,81(5):998-1004.
[14]	Ji P,Diederichs S,Wang W,et al.MALAT-1,a novel noncoding RNA,and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer[J].Oncogene,2003,22(39):8031-8041.
[15]	Ren S,Peng Z,Mao J H,et al.RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions,cancer-associated long noncoding RNAs and aberrant alternative splicings[J].Cell Res,2012,22(5):806-821.
[16]	Wang F,Ren S1,Chen R,et al.Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1as a diagnostic urinary biomarker for prostate cancer[J].Oncotarget,2014,5(22):11091-11102.
[17]	Lan H,Lu H,Wang X,et al.MicroRNAs as potential biomarkers in cancer:opportunities and challenges[J].Biomed Res Int,2015,2015:125094.
[18]	Porkka K P,Pfeiffer M J,Waltering K K,et al.MicroRNA expression profiling in prostate cancer[J].Cancer Res,2007,67(13):6130-6135.
[19]	Gordanpour A,Nam R K,Sugar L,et al.MicroRNAs in prostate cancer:from biomarkers to molecularlybased therapeutics[J].Prostate Cancer Prostatic Dis,2012,15(4):314-319.
[20]	Schaefer A,Jung M,Mollenkopf H J,et al.Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma[J].Int J Cancer,2010,126(5):1166-1176.
[21]	StuopelytèK,DaniūnaitèK,Jankevicius F,et al.Detection of miRNAs in urine of prostate cancer patients[J].Medicina(Kaunas),2016,52(2):116-124.
[22]	Hashemi M,Moradi N,Ziaee S A,et al.Association between single nucleotide polymorphism in miR-499,miR-196a2,miR-146aand miR-149and prostate cancer risk in a sample of Iranian population[J].J Adv Res,2016,7(3):491-498.
[23]	EndzelinšE,Melne V,Kalnina Z,et al.Diagnostic,prognostic and predictive value of cell-free miRNAs in prostate cancer:a systematic review[J].Mol Cancer,2016,15(1):41.
[24]	Tomlins S A,Rhodes D R,Perner S,et al.Recurrent fusion of TMPRSS2and ETS transcription factor genes in prostate cancer[J].Science,2005,310(5748):644-648.
[25]	Laxman B,Tomlins S A,Mehra R,et al.Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer[J].Neoplasia,2006,8(10):885-888.
[26]	Miyagi Y,Sasaki T,Fujinami K,et al.ETS familyassociated gene fusions in Japanese prostate cancer:analysis of 194radical prostatectomy samples[J].Mod Pathol,2010,23(11):1492-1498.
[27]	Wang J J,Liu Y X,Wang W,et al.Fusion between TMPRSS2and ETS family members(ERG,ETV1,ETV4)in prostate cancers from northern China[J].A-sian Pac J Cancer Prev,2012,13(10):4935-4938.
[28]	Salami S S,Schmidt F,Laxman B,et al.Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer[J].Urol Oncol,2013,31(5):566-571.
[29]	Stephan C,Jung K,Semjonow A,et al.Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum[-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer[J].Clin Chem,2013,59(1):280-288.
[30]	Berg K D,Vainer B,Thomsen F B,et al.ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer[J].Eur Urol,2014,66(5):851-860.
[31]	Lin D W,Newcomb L F,Brown E C,et al.Urinary TMPRSS2:ERG and PCA3in an active surveillance cohort:results from a baseline analysis in the Canary Prostate Active Surveillance Study[J].Clin Cancer Res,2013.19(9):2442-2450.
[32]	Nam R K,Sugar L,Yang W,et al.Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer[J].Br JCancer,2007,97(12):1690-1695.
[33]	Pettersson A,Graff R E,Bauer S R,et al.The TM-PRSS2:ERG rearrangement,ERG expression,and prostate cancer outcomes:a cohort study and meta-analysis[J].Cancer Epidemiol Biomarkers Prev,2012,21(9):1497-1509.
[34]	Van Neste L,Herman J G,Otto G,et al.The epigenetic promise for prostate cancer diagnosis[J].Prostate,2012,72(11):1248-1261.
[35]	Stewart G D,Van Neste L,Delvenne P,et al.Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies:results of the MATLOC study[J].J Urol,2013,189(3):1110-1116.
[36]	Partin A W,Van Neste L,Klein E A,et al.Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies[J].JUrol,2014,192(4):1081-1087.
[37]	Saal L H,Johansson P,Holm K,et al.Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity[J].Proc Natl Acad Sci U S A,2007,104(18):7564-7569.
[38]	Leinonen K A,Saramäki O R,Furusato B,et al.Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer[J].Cancer Epidemiol Biomarkers Prev,2013,22(12):2333-2344.
[39]	Krohn A,Diedler T,Burkhardt L,et al.Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer[J].Am J Pathol,2012,181(2):401-412.
[40]	Parr R L,Mills J,Harbottle A,et al.Mitochondria,prostate cancer,and biopsy sampling error[J].Discov Med,2013,15(83):213-220.
[41]	Maki J,Robinson K,Reguly B,et al.Mitochondrial genome deletion aids in the identification of false-and true-negative prostate needle core biopsy specimens[J].Am J Clin Pathol,2008,129(1):57-66.
[42]	Maragh S,Veltri R W,Lund S P,et al.Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection[J].Cancer Biomark,2015,15(6):763-773.